市場調査レポート

商品コード

次世代薬物複合体市場-GalNac/ペプチド薬物/ペプチドオリゴヌクレオチド＆RNAi複合体、ペプチド受容体放射性核種療法、その他の複合体-主要地域：業界動向と世界の予測、2023年～2035年

Next Generation Drug Conjugates Market-Focus on GalNac/Peptide Drug/Peptide Oligonucleotide & RNAi Conjugate, Peptide Receptor Radionuclide Therapy, & Other Conjugates-Key Geographical Regions: Industry Trends & Global Forecasts, 2023-2035

出版日: 2023年09月01日 | 発行: Roots Analysis

| ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,799 754,114円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,099,822円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,665,526円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,828,362円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

次世代薬物複合体の市場情勢は、次世代薬物複合体の開発に従事する大手、中堅、中小の参入企業が30社以上存在し、集中しています。現在、200を超える次世代薬物複合体が承認されているか、臨床研究のさまざまな段階で評価されており、そのうち50％以上が前臨床／探索段階にあります。

注目すべきは、薬剤候補の40％近くと30％近くが、それぞれ腫瘍性疾患と希少疾患の治療薬として、さまざまな開発段階で研究されていることです。これらの薬剤候補は、有望な標的治療薬として浮上しています。さらに、低分子-薬物複合体（SMDC）、ペプチド薬物複合体、GalNac複合体など、さまざまな次世代薬物複合体に焦点を当てた260以上の臨床試験が2018年以降実施されており、この業界に従事する研究者による多大な努力が示されています。

ここ数年の製薬業界におけるブレークスルーにより、様々な新しいタイプの薬剤様式が開発されています。次世代薬物複合体は、希少疾患や腫瘍性疾患の標的治療薬として登場した多くの新しい薬物療法のひとつです。興味深いことに、ペプチド薬物複合体はその構造と作用機序から、抗体薬物複合体に代わる可能性のある薬物として浮上してきました。Oncopeptides社が開発したPepaxtoは、2021年2月に再発または難治性の多発性骨髄腫の治療薬としてFDAから加速承認を受けた最初の抗がん剤ペプチド薬物複合体でした。しかし、第III相臨床試験で思わしくない結果が出たため、2021年10月に米国市場から撤退しました。

過去10年間で、オリゴヌクレオチド治療薬は有望な治療手段として浮上してきました。その中でもGalNAc複合体は最近、様々な希少疾患に対する画期的な治療法として浮上しています。GalNAc複合体は、オリゴヌクレオチドに結合したN-アセチルガラクトサミン（GalNAc）糖分子からなります。GalNAc分子は肝細胞のアシアロ糖タンパク質受容体（ASGPR）と結合する親和性があることから、GalNAc結合オリゴヌクレオチド療法は、肝細胞を通して治療手段を送達するための主要な戦略として浮上しました。

研究開発活動の増加と、希少疾患やがん疾患に対する効果的な治療法に対する需要の高まりに後押しされ、次世代薬剤複合体の市場規模は、2023年～2035年の間に20%を超える年率成長率（CAGR）で拡大すると予測されています。具体的には、複合体タイプ別では、次世代薬物複合体の世界市場はGalNac複合体によって牽引されると予想されます。同様に、治療領域別では、希少疾患や腫瘍性疾患を標的とする複合体が市場を独占すると予想されます。

加えて、北米を拠点とする企業が70％以上の市場シェアを獲得しており、そのうち60％は米国を拠点としています。次いで、多くの開発企業が次世代薬物複合体の開発に取り組んでいるアジア太平洋が続きます。興味深いことに、アジア太平洋では中国が次世代薬物複合体の開発企業の大半が拠点を置く主要国として浮上しています。

ペプチド薬物複合体、GalNac複合体、ペプチド放射性核種治療を利用した複合体（ペプチド放射性核種複合体）など、さまざまな次世代薬物複合体の最近の早期承認に加え、USFDAやEMAなどの規制当局による希少疾病用医薬品（オーファン）指定や画期的治療薬（ブレークスルー）指定により、これらの新規標的治療薬に対する製薬業界全体の関心と信頼が高まっています。上記の要因はすべて、予測期間中の次世代薬物複合体市場の健全な成長に寄与するとみられていまます。

当レポートでは、世界の次世代薬物複合体市場について調査し、市場の概要とともに、臨床試験の動向、主要地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 4.1. Next Generation Drug Conjugates: List of Therapies
Table 4.2. Next Generation Drug Conjugates: List of Developers
Table 5.1. Advance Accelerator Applications: Product Portfolio
Table 5.2. Lutathera®: Drug Overview
Table 5.3. Lutathera®: Clinical Trial Information
Table 5.4 Lutathera®: Dosing Regimen
Table 5.5 Pluvicto®: Drug Overview
Table 5.6 Pluvicto®: Clinical Trial Information
Table 5.7 Pluvicto®: Dosing Regimen
Table 5.8 Advance Accelerator Applications: Recent Developments and Future Outlook
Table 5.9. Alnylam Pharmaceuticals: Product Portfolio
Table 5.10. Givlaari®: Drug Overview
Table 5.11. Givlaari®: Clinical Trial Information
Table 5.12 Givlaari®: Dosing Regimen
Table 5.13. Oxlumo®: Drug Overview
Table 5.14. Oxlumo®: Clinical Trial Information
Table 5.15 Oxlumo®: Dosing Regimen
Table 5.16. Leqvio®: Drug Overview
Table 5.17. Leqvio®: Clinical Trial Information
Table 5.18. Leqvio®: Dosing Regimen
Table 5.19. Amvuttra®: Drug Overview
Table 5.20. Amvuttra®: Clinical Trial Information
Table 5.21. Amvuttra®: Dosing Regimen
Table 5.22. Alnylam Pharmaceuticals: Recent Developments and Future Outlook
Table 5.23. Arrowhead Pharmaceuticals: Product Portfolio
Table 5.24. Olapsiran: Drug Overview
Table 5.25. Olpasiran: Clinical Trial Information
Table 5.26 Olapsiran: Dosing Regimen
Table 5.27. ARO-AAT: Drug Overview
Table 5.28. ARO-AAT: Clinical Trial Information
Table 5.29 ARO-AAT: Dosing Regimen
Table 5.30. ARO-APOC3: Drug Overview
Table 5.31. ARO-APOC3: Clinical Trial Information
Table 5.32 ARO-APOC3: Dosing Regimen
Table 5.33. Arrowhead Pharmaceuticals: Recent Developments and Future Outlook
Table 5.34. Dicerna Pharmaceuticals: Product Portfolio
Table 5.35. Nedosiran: Drug Overview
Table 5.36. Nedosiran: Clinical Trial Information
Table 5.37 Nedosiran: Dosing Regimen
Table 5.38. Dicerna Pharmaceuticals: Recent Developments and Future Outlook
Table 5.39. Geron: Product Portfolio
Table 5.40. Imtelstat: Drug Overview
Table 5.41. Imtelstat: Clinical Trial Information
Table 5.42 Imtelstat: Dosing Regimen
Table 5.43. Geron: Recent Developments and Future Outlook
Table 5.44. Ionis Pharmaceuticals: Product Portfolio
Table 5.45. Eplontersen (Transthyretin-Mediated Amyloidosis - Polyneuropathy): Drug Overview
Table 5.46. Eplontersen (Transthyretin-Mediated Amyloidosis - Polyneuropathy): Clinical Trial Information
Table 5.47 Eplontersen (Transthyretin-Mediated Amyloidosis - Polyneuropathy): Dosing Regimen
Table 5.48. Eplontersen (Transthyretin-Mediated Amyloidosis - Cardiomyopathy): Drug Overview
Table 5.49. Eplontersen (Transthyretin-Mediated Amyloidosis - Cardiomyopathy): Clinical Trial Information
Table 5.50. Eplontersen (Transthyretin-Mediated Amyloidosis - Cardiomyopathy): Dosing Regimen
Table 5.51. Olezarsen: Drug Overview
Table 5.52. Olezarsen: Clinical Trial Information
Table 5.53. Olezarsen: Dosing Regimen
Table 5.54. Pelacarsen: Drug Overview
Table 5.55. Pelacarsen: Clinical Trial Information
Table 5.56. Pelacarsen: Dosing Regimen
Table 5.57. Donidalorsen: Drug Overview
Table 5.58. Donidalorsen: Clinical Trial Information
Table 5.59. Donidalorsen: Dosing Regimen
Table 5.60. Ionis Pharmaceuticals: Recent Developments and Future Outlook
Table 6.1. Next Generation Drug Conjugates: List of Clinical Trials (Sample Data, Pre-2017-2023)
Table 7.1. Next Generation Drug Conjugates: List of Partnerships and Collaborations (2018-2023)
Table 8.1. Next Generation Drug Conjugates: List of Academic Grants (Sample Data, Pre-2021-2023)
Table 9.1. Next Generation Drug Conjugates: List of Publications (Sample Data, 2018-2023)
Table 10.1. Next Generation Drug Conjugates: List of Failed Drugs
Table 12.1. Next Generation Drug Conjugates Market: List of Forecasted Drugs
Table 13.1 Next Generation Drug Conjugates: Distribution by Type of Conjugate
Table 13.2. Next Generation Drug Conjugates: Distribution by Type of Targeting Ligand
Table 13.3. Next Generation Drug Conjugates: Distribution by Type of Payload
Table 13.4. Next Generation Drug Conjugates: Distribution by Biological Target
Table 13.5. Next Generation Drug Conjugates: Distribution by Mechanism of Action
Table 13.6. Next Generation Drug Conjugates: Distribution by Stage of Development
Table 13.7. Next Generation Drug Conjugates: Distribution by Phase of Development
Table 13.8. Next Generation Drug Conjugates: Distribution by Type of Therapy
Table 13.9. Next Generation Drug Conjugates: Distribution by Route of Administration
Table 13.10. Next Generation Drug Conjugates: Distribution by Target Disease Indication
Table 13.11. Next Generation Drug Conjugates: Distribution by Therapeutic Area
Table 13.12. Next Generation Drug Conjugates: Distribution by Target Population
Table 13.13. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Stage of Development
Table 13.14. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Target Population
Table 13.15. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment
Table 13.16. Next Generation Drug Conjugate Developers: Distribution by Company Size
Table 13.17. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Region-wise)
Table 13.18. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Country-wise)
Table 13.19. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
Table 13.20. Most Active Players: Distribution by Number of Drug Candidates
Table 13.21. Clinical Trial Analysis: Distribution by Trial Registration Year
Table 13.22. Clinical Trial Analysis: Distribution by Trial Phase
Table 13.23. Clinical Trial Analysis: Distribution by Trial Status
Table 13.24. Clinical Trial Analysis: Distribution by Therapeutic Area
Table 13.25. Clinical Trial Analysis: Distribution by Primary Purpose
Table 13.26. Clinical Trial Analysis: Distribution by Age Group
Table 13.27. Clinical Trial Analysis: Distribution by Type of Sponsor
Table 13.28. Most Active Industry Players: Analysis by Number of Trials
Table 13.29. Leading Drug Candidates: Analysis by Number of Trials
Table 13.30. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Location
Table 13.31. Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 13.32. Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Table 13.33. Clinical Trial Analysis: Distribution by Trial Status and Enrolled Patient Population
Table 13.34. Clinical Trial Analysis: Distribution by Trial Location and Enrolled Patient Population
Table 13.35. Clinical Trial Analysis: Distribution by Trial Status and Trial Location
Table 13.36. Partnerships and Collaborations: Distribution by Year of Partnership
Table 13.37. Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.38. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 13.39. Partnerships and Collaborations: Distribution by Type of Partner
Table 13.40. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 13.41. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 13.42. Partnerships and Collaborations: Distribution by Type of Partner and Parent Company Size
Table 13.43. Partnerships and Collaborations: Distribution by Therapeutic Area
Table 13.44. Most Active Players: Analysis by Number of Partnerships
Table 13.45. Partnerships and Collaborations: Distribution by Type of Geography (Region-wise)
Table 13.46. Partnerships and Collaborations: Distribution by Type of Geography (Country-wise)
Table 13.47. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 13.48. Academic Grants Analysis: Distribution by Year of Grant Award
Table 13.49. Academic Grants Analysis: Distribution by Amount Awarded
Table 13.50 Academic Grants Analysis: Distribution by Funding Institute Center
Table 13.51. Academic Grants Analysis: Distribution by Support Period
Table 13.52. Academic Grants Analysis: Distribution by Funding Institute Center and Support Period
Table 13.53. Academic Grants Analysis: Distribution by Type of Grant Application
Table 13.54. Academic Grants Analysis: Distribution by Purpose of Grant
Table 13.55. Academic Grants Analysis: Distribution by Activity Code
Table 13.56. Academic Grants Analysis: Distribution by Study Section
Table 13.57 Popular NIH Departments: Analysis by Number of Grants
Table 13.58. Popular Recipient Organizations: Distribution by Number of Grants
Table 13.59. Popular Recipient Organizations: Distribution by Amount Awarded
Table 13.60 Prominent Program Officers: Analysis by Number of Grants
Table 13.61. Academic Grants Analysis: Distribution by Location of Recipient Organizations
Table 13.62. Publication Analysis: Distribution by Year of Publication
Table 13.63. Publication Analysis: Distribution by Type of Publication
Table 13.64. Publication Analysis: Distribution by Type of Conjugate
Table 13.65. Publication Analysis: Distribution by Target Indication
Table 13.66. Publication Analysis: Distribution by Copyright Holder
Table 13.67. Word Cloud: Emerging Focus Area
Table 13.68. Most Active Publishers: Analysis by Number of Publications
Table 13.69. Key Journals: Analysis by Number of Publications
Table 13.70. Key Journals: Analysis by Impact Factor
Table 13.71. Drug Failure Analysis: Distribution by Status of Discontinuation
Table 13.72. Drug Failure Analysis: Distribution by Phase of Discontinuation
Table 13.73. Drug Failure Analysis: Distribution by Average Trial Year
Table 13.74. Drug Failure Analysis: Distribution by Type of Therapy
Table 13.75. Drug Failure Analysis: Distribution by Target Indication
Table 13.76 Drug Failure Analysis: Distribution by Reason of Drug Failure
Table 13.77. Global Next Generation Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.78. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035 (USD Million)
Table 13.79. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.80. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicines, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.81. Next Generation Drug Conjugates: Distribution for Ligand mediated RNAi Conjugates, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.82. Next Generation Drug Conjugates Market for by Peptide Drug Conjugates, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.83. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand, 2023 and 2035 (USD Million)
Table 13.84. Next Generation Drug Conjugates Market: Distribution for Amino Sugars, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.85. Next Generation Drug Conjugates Market for Peptides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.86. Next Generation Drug Conjugates Market for Lipids, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.87. Next Generation Drug Conjugates Market: Distribution by Payload, Conservative, Base and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 13.88. Next Generation Drug Conjugates Market for Radionuclides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.89. Next Generation Drug Conjugates Market for Drugs, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.90. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.91. Next Generation Drug Conjugates Market for si-RNAs, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.92. Next Generation Drug Conjugates Market: Distribution by Type of Therapy, 2023 and 2035 (USD Million)
Table 13.93. Next Generation Drug Conjugates Market for Monotherapy, Conservative, Base and Optimistic Scenario, 2023 and 2035 (USD Million)
Table 13.94. Next Generation Drug Conjugates Market for Combination Therapy, Conservative, Base and Optimistic Scenario, 2023 and 2035 (USD Million)
Table 13.95. Next Generation Drug Conjugates Market: Distribution by Route of Administration, 2023 and 2035 (USD Million)
Table 13.96. Next Generation Intravenous Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.947 Next Generation Subcutaneous Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.98. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Million)
Table 13.99. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.100. Next Generation Drug Conjugates Market for Prostate Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.101. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.102. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.103. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.104. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.105. Next Generation Drug Conjugates Market for Hereditary Angioedema, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.106. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.107. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.108. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.109. Next Generation Drug Conjugates Market for Hemophilia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.110. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.111. Next Generation Drug Conjugates Market for Myelofibrosis, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.112. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.113. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.114. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 13.115. Next Generation Drug Conjugates Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.116. Next Generation Drug Conjugates Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.117. Next Generation Drug Conjugates Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.118. Next Generation Drug Conjugates Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.119. Next Generation Drug Conjugates Market in the UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.120. Next Generation Drug Conjugates Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.121. Next Generation Drug Conjugates Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.122. Next Generation Drug Conjugates Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.123. Next Generation Drug Conjugates Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.124. Next Generation Drug Conjugates Market in Rest of the Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.125. Next Generation Drug Conjugates Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.126. Next Generation Drug Conjugates Market in Japan, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.127. Next Generation Drug Conjugates Market in Australia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.128. Next Generation Drug Conjugates Market in Brazil, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.129. Lutathera®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.130. Pluvicto®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.131. Givlaari®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.132. Oxlumo®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.133. Leqvio®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.134. Amvuttra®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.135. Eplontersen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.136. Olezarsen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.137. Pelacarsen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.138. Donidalorsen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.139. Fitusiran: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.140. Nedosiran: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.141. Imetlestat: Sales Forecast, Conservative, Base and Optimistic Scenarios, 20232035 (USD Million)
Table 13.142. Olpasiran: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.143. ARO-AAT: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.144. ARO-APOC3: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.145. ANG-1005: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)

List of Figures

Figure 3.1. Key Historical Events
Figure 3.2. Structure of Next Generation Drug Conjugates
Figure 3.3. Biochemical Interaction and Mechanism of Action
Figure 3.4. Key Target Indications
Figure 4.1 Next Generation Drug Conjugates: Distribution by Type of Conjugate
Figure 4.2. Next Generation Drug Conjugates: Distribution by Type of Targeting Ligand
Figure 4.3. Next Generation Drug Conjugates: Distribution by Type of Payload
Figure 4.4. Next Generation Drug Conjugates: Distribution by Biological Target
Figure 4.5. Next Generation Drug Conjugates: Distribution by Mechanism of Action
Figure 4.6. Next Generation Drug Conjugates: Distribution by Stage of Development
Figure 4.7. Next Generation Drug Conjugates: Distribution by Phase of Development
Figure 4.8. Next Generation Drug Conjugates: Distribution by Type of Therapy
Figure 4.9. Next Generation Drug Conjugates: Distribution by Route of Administration
Figure 4.10. Next Generation Drug Conjugates: Distribution by Target Disease Indication
Figure 4.11. Next Generation Drug Conjugates: Distribution by Therapeutic Area
Figure 4.12. Next Generation Drug Conjugates: Distribution by Target Population
Figure 4.13. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Stage of Development
Figure 4.14. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Target Population
Figure 4.15. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment
Figure 4.16. Next Generation Drug Conjugate Developers: Distribution by Company Size
Figure 4.17. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.19. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
Figure 4.20. Most Active Players: Distribution by Number of Drug Candidates
Figure 6.1. Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 6.2. Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3. Clinical Trial Analysis: Distribution by Trial Status
Figure 6.4. Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 6.5. Clinical Trial Analysis: Distribution by Primary Purpose
Figure 6.6. Clinical Trial Analysis: Distribution by Age Group
Figure 6.7. Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 6.8. Most Active Industry Players: Distribution by Number of Trials
Figure 6.9. Leading Drug Candidates: Distribution by Number of Trials
Figure 6.10. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Location
Figure 6.11. Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 6.12. Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Figure 6.13. Clinical Trial Analysis: Distribution by Trial Status and Enrolled Patient Population
Figure 6.14. Clinical Trial Analysis: Distribution by Trial Location and Enrolled Patient Population
Figure 6.15. Clinical Trial Analysis: Distribution by Trial Status and Trial Location
Figure 7.1. Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4. Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.5. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.7. Partnerships and Collaborations: Distribution by Type of Partner and Parent Company Size
Figure 7.8. Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 7.9. Most Active Players: Distribution by Number of Partnerships
Figure 7.10. Partnerships and Collaborations: Distribution by Type of Geography (Region-wise)
Figure 7.11. Partnerships and Collaborations: Distribution by Type of Geography (Country-wise)
Figure 7.12. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.1. Academic Grants Analysis: Distribution by Year of Grant Award
Figure 8.2. Academic Grants Analysis: Distribution by Amount Awarded
Figure 8.3. Academic Grants Analysis: Distribution by Funding Institute Center
Figure 8.4. Academic Grants Analysis: Distribution by Support Period
Figure 8.5. Academic Grants Analysis: Distribution by Funding Institute Center and Support Period
Figure 8.6. Academic Grants Analysis: Distribution by Type of Grant Application
Figure 8.7. Academic Grants Analysis: Distribution by Purpose of Grant
Figure 8.8. Academic Grants Analysis: Distribution by Activity Code
Figure 8.9. Academic Grants Analysis: Distribution by Study Section
Figure 8.10 Popular NIH Departments: Distribution by Number of Grants
Figure 8.12. Popular Recipient Organization: Distribution by Number of Grants
Figure 8.13. Popular Recipient Organization: Distribution by Amount Awarded
Figure 8.14 Prominent Program Officers: Distribution by Number of Grants
Figure 8.15. Academic Grants Analysis: Distribution by Location of Recipient Organizations
Figure 9.1. Publication Analysis: Distribution by Year of Publication
Figure 9.2. Publication Analysis: Distribution by Type of Publication
Figure 9.3. Publication Analysis: Distribution by Type of Conjugate
Figure 9.4. Publication Analysis: Distribution by Target Indication
Figure 9.5. Publication Analysis: Distribution by Copyright Holder
Figure 9.6. Word Cloud: Emerging Focus Area
Figure 9.7. Most Active Publishers: Distribution by Number of Publications
Figure 9.8. Key Journals: Distribution by Number of Publications
Figure 9.9. Key Journals: Distribution by Impact Factor
Figure 10.1. Drug Failure Analysis: Distribution by Status of Discontinuation
Figure 10.2. Drug Failure Analysis: Distribution by Phase of Discontinuation
Figure 10.3. Drug Failure Analysis: Distribution by Average Trial Year
Figure 10.4. Drug Failure Analysis: Distribution by Type of Therapy
Figure 10.5. Drug Failure Analysis: Distribution by Target Indication
Figure 10.6. Drug Failure Analysis: Distribution by Reason for Drug Failure
Figure 11.1. Success Protocol Analysis: Lutathera (Gastroenteropancreatic Neuroendocrine Tumor)
Figure 11.2. Success Protocol Analysis: Pluvicto® (Prostate Cancer)
Figure 11.3. Success Protocol Analysis: Givlaari® (Acute Hepatic Porphyria)
Figure 11.4 Success Protocol Analysis: Oxlumo® (Primary Hyperoxaluria)
Figure 11.5 Success Protocol Analysis: Amvuttra® (Hereditary ATTR Amyloidosis)
Figure 11.6 Success Protocol Analysis: Leqvio® (Heterozygous Familial Hypercholesterolemia)
Figure 11.7 Success Protocol Analysis: Overall Assessment of Approved Next Generation Drug Conjugates
Figure 12.1. Global Next Generation Drug Conjugates Market, 2023-2035 (USD Million)
Figure 12.2. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035 (USD Million)
Figure 12.3. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, 2023-2035 (USD Million)
Figure 12.4. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, 2023-2035 (USD Million)
Figure 12.5 Next Generation Drug Conjugates Market for Ligand mediated RNAi Conjugates, 2023-2035 (USD Million)
Figure 12.6. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, 2023-2035 (USD Million)
Figure 12.7. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand, 2023 and 2035 (USD Million)
Figure 12.8. Next Generation Drug Conjugates Market for Amino Sugars, 2023-2035 (USD Million)
Figure 12.9 Next Generation Drug Conjugates Market for Peptides, 2023-2035 (USD Million)
Figure 12.10. Next Generation Drug Conjugates Market for Lipids, 2023-2035 (USD Million)
Figure 12.11. Next Generation Drug Conjugates Market: Distribution by Payload, 2023 and 2035 (USD Million)
Figure 12.12. Next Generation Drug Conjugates Market for Radionuclides, 2023-2035 (USD Million)
Figure 12.13. Next Generation Drug Conjugates Market for Drugs, 2023-2035 (USD Million)
Figure 12.14. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, 2023-2035 (USD Million)
Figure 12.15. Next Generation Drug Conjugates Market for si-RNAs, 2023-2035 (USD Million)
Figure 12.16. Next Generation Drug Conjugates Market: Distribution by Therapy, 2023 and 2035 (USD Million)
Figure 12.17 Next Generation Drug Conjugates Market for Monotherapy, 2023-2035 (USD Million)
Figure 12.18. Next Generation Drug Conjugates Market for Combination Therapy 2023-2035 (USD Million)
Figure 12.19 Next Generation Drug Conjugates Market: Distribution by Route of Administration, 2023 and 2035 (USD Million)
Figure 12.20. Next Generation Intravenous Drug Conjugates Market, 2023-2035 (USD Million)
Figure 12.21. Next Generation Subcutaneous Drug Conjugates Market, 2023-2035 (USD Million)
Figure 12.22. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Million)
Figure 12.23. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, 2023-2035 (USD Million)
Figure 12.24. Next Generation Drug Conjugates Market for Prostate Cancer, 2023-2035 (USD Million)
Figure 12.25. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis, 2023-2035 (USD Million)
Figure 12.26. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, 2023-2035 (USD Million)
Figure 12.27. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, 2023-2035 (USD Million)
Figure 12.28. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, 2023-2035 (USD Million)
Figure 12.29. Next Generation Drug Conjugates Market for Hereditary Angioedema, 2023-2035 (USD Million)
Figure 12.30. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, 2023-2035 (USD Million)
Figure 12.31. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, 2023-2035 (USD Million)
Figure 12.32. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, 2023-2035 (USD Million)
Figure 12.33. Next Generation Drug Conjugates Market for Hemophilia, 2023-2035 (USD Million)
Figure 12.34. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, 2023-2035 (USD Million)
Figure 12.35. Next Generation Drug Conjugates Market for Myelofibrosis, 2023-2035 (USD Million)
Figure 12.36. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, 2023-2035 (USD Million)
Figure 12.37. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, 2023-2035 (USD Million)
Figure 12.38. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 12.39. Next Generation Drug Conjugates Market in North America, 2023-2035 (USD Million)
Figure 12.40. Next Generation Drug Conjugates Market in the US, 2023-2035 (USD Million)
Figure 12.41. Next Generation Drug Conjugates Market in Canada, 2023-2035 (USD Million)
Figure 12.42. Next Generation Drug Conjugates Market in Europe, 2023-2035 (USD Million)
Figure 12.43. Next Generation Drug Conjugates Market in the UK, 2023-2035 (USD Million)
Figure 12.44. Next Generation Drug Conjugates Market in France, 2023-2035 (USD Million)
Figure 12.45. Next Generation Drug Conjugates Market in Germany, 2023-2035 (USD Million)
Figure 12.46. Next Generation Drug Conjugates Market in Spain, 2023-2035 (USD Million)
Figure 12.47. Next Generation Drug Conjugates Market in Italy, 2023-2035 (USD Million)
Figure 12.48. Next Generation Drug Conjugates Market in Rest of the Europe, 2023-2035 (USD Million)
Figure 12.49. Next Generation Drug Conjugates Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 12.50. Next Generation Drug Conjugates Market in Japan, 2023-2035 (USD Million)
Figure 12.51. Next Generation Drug Conjugates Market in Australia, 2023-2035 (USD Million)
Figure 12.52. Next Generation Drug Conjugates Market in Brazil, 2023-2035 (USD Million)
Figure 12.53. Lutathera®: Sales Forecast (USD Million)
Figure 12.54. Pluvicto®: Sales Forecast (USD Million)
Figure 12.55. Givlaari®: Sales Forecast (USD Million)
Figure 12.56. Oxlumo®: Sales Forecast (USD Million)
Figure 12.57. Leqvio®: Sales Forecast (USD Million)
Figure 12.58. Amvuttra®: Sales Forecast (USD Million)
Figure 12.59. Eplontersen: Sales Forecast (USD Million)
Figure 12.60. Olezarsen: Sales Forecast (USD Million)
Figure 12.61. Pelacarsen: Sales Forecast (USD Million)
Figure 12.62. Donidalorsen: Sales Forecast (USD Million)
Figure 12.63. Fitusiran: Sales Forecast (USD Million)
Figure 12.64. Nedosiran: Sales Forecast (USD Million)
Figure 12.65. Imetlestat: Sales Forecast (USD Million)
Figure 12.66. Olpasiran: Sales Forecast (USD Million)
Figure 12.67. ARO-AAT: Sales Forecast (USD Million)
Figure 12.68. ARO-APOC3: Sales Forecast (USD Million)
Figure 12.69. ANG-1005: Sales Forecast (USD Million)

Product Code: RA100455

INTRODUCTION

The global market for the next generation drug conjugates is expected to grow at a compounded annual growth rate (CAGR) of more than 20% during the forecast period.

The next generation drug conjugates, owing to their non-immunogenic nature, better clinical profile, structural stability, limited side effects, targeted delivery of payload, deeper cellular penetration, and permeability, have emerged as the viable targeted therapeutics for rare disease indications, including cancers. Over the last decade, the standard cost of medical care for rare disease indications has increased exponentially. Specifically, in the US, close to USD 1 trillion was spent for medical care for rare diseases in 2020. Further, the average cost incurred by a patient suffering from a rare disease condition was USD 60,248 in 2020, which if taken into account is twice the average cost incurred by any general patient. The incremental rise in medicare cost, coupled with the rising burden of rare disease indications globally, prompted the stakeholders to look for alternatives to the conventional therapies, and next generation drug conjugates have emerged as a promising treatment option.

Owing to the structural similarity with antibody drug conjugates (ADCs), and various advantages related to clinical efficacy and stability over ADCs, the next generation drug conjugates have emerged as its direct viable alternative. Similar to ADCs, the next generation drug conjugates utilize a targeting ligand, a linker and a payload for the targeted delivery. However, unlike ADCs, which use antibody as the targeting ligand, the next generation drug conjugates utilize various non-antibody-based targeting ligands, such as peptides, amino sugar, lipid, and small molecule as their targeting agent. Further, in place of drug, it utilizes oligonucleotide, antisense oligonucleotide, si-RNA, drug, and radionuclide as their payload.

As a result of various synergistic combinations with the targeting ligand and payload, various types of next generation drug conjugates, such as peptide drug conjugate, peptide receptor radionuclide therapy (peptide radionuclide conjugate), GalNac conjugates, peptide oligonucleotide conjugate, si-RNA conjugate, small molecule-drug conjugate (SMDC), ligand conjugated anti sense medicine (LICA), and peptide conjugated phosphorodiamidate morpholino oligomers (PPMO) have emerged in the domain of targeted therapeutics. The success of these next generation drug conjugates can be attributed to their clinical effectiveness, and its ability to target wide range of therapeutic modalities, including solid tumors, multiple myeloma, metabolic disorders, and hematological disorders. Till date, six next generation drug conjugates have been approved by the USFDA for therapeutic purposes, which include Lutathera® and Pluvicto®, peptide receptor radionuclide therapy, developed by Advanced Accelerator Applications, and Givlaari®, Oxlumo®, Leqvio® and Amvuttra® (GalNac conjugates) developed by Alnylam Pharmaceuticals.

With the ongoing pace of innovation in this field, encouraging clinical trial results, accelerated approvals, and the continuous efforts of both industry and non-industry players, the next generation drug conjugates market is likely to witness significant growth during the forecast period.

SCOPE OF THE REPORT

"The Next Generation Drug Conjugates Market: Focus on GalNac Conjugate, Peptide Drug Conjugate, Peptide Oligonucleotide Conjugate, RNAi Conjugate, Peptide Receptor Radionuclide Therapy, Small Molecule-Drug Conjugate (SMDC), and Other Conjugates - Distribution by Type of Targeting Ligand (Amino Sugar, Lipid, Peptide, Small Molecule and Virus-like Particles), Type of Payload (Peptide, Small Molecule, Oligonucleotide and Radionuclide), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Subcutaneous and Others), Mechanism of Action (sequence-specific target binding, radiation induced cytotoxicity, cancer-specific surface target mediated cytotoxicity, drug induced cytotoxicity, receptor mediated internalization and cytotoxicity and others) and Key Target Indications (Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Primary Hyperoxaluria, Heterozygous Familial Hypercholesterolemia, Hemophilia, Low-Risk Myelodysplastic Syndrome, Myelofibrosis, Alpha-1 Antitrypsin Deficiency Liver Disease and Familial Chylomicronemia Syndrome) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035" report features an extensive study of the current market landscape, market size and future opportunities in the next generation drug conjugates market, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.

Key takeaways of the next generation drug conjugates market are briefly discussed below.

Current Market Landscape: Next Generation Drug Conjugates Revolutionizing the Treatment for Cancer and Rare Diseases

The next generation drug conjugates market landscape is concentrated with the presence of over 30 large, mid-sized and small players engaged in the development of next generation drug conjugates. Currently, over 200 next generation drug conjugates are either approved or being evaluated in various stages of clinical research; of these, more than 50% of the drug candidates are in preclinical / discovery phase.

It is worth highlighting that close to 40% and 30% of the drug candidates are being investigated for the treatment of oncological and rare diseases, respectively, in different phases of development. These drug candidates have emerged as a promising targeted therapy. Further, over 260 clinical trials focused on various next generation drug conjugates, such as small molecule-drug conjugates (SMDC), peptide drug conjugates, GalNac conjugates, and others have been conducted since 2018, indicating the substantial efforts made by researchers engaged in this industry.

Peptide Drug Conjugate, Next Generation of Targeted Therapeutics in Clinical Trial as Anticancer Agents

Breakthrough in the pharmaceutical industry in the last few years has led to the development of various new types of drug modalities. Next Generation Drug Conjugates are one of the many new drug modalities, which have surfaced as targeted therapies for rare disorders and oncological disorders. Interestingly, owing to their structure and mechanism of action, peptide drug conjugate have emerged as a possible alternative to the antibody drug conjugates. Pepaxto, developed by Oncopeptides was the first anticancer peptide drug conjugate to receive accelerated approval from the FDA for the treatment of relapsed or refractory multiple myeloma in February 2021. However, the drug was withdrawn from the US market in October 2021 due to unfavorable results in a phase III clinical trial.

In American Society of Clinical Oncology (ASCO) 2023 annual meeting, clinical trial results of two peptide drug conjugate were presented, which include preliminary results from phase I clinical trials of Cybrexa Therapeutics / Exelixis' CBX-12 and Theratechnologies' TH1902. Additionally, there are about 10 peptide drug conjugate candidates, which are being evaluated either as monotherapy or combination therapy in active clinical trials. Further, it is worth highlighting that UK based Bicycle Therapeutics is leading the development of this novel drug class. In February 2023, Bicycle Therapeutics presented results from phase I portion of an ongoing phase I/II clinical trial of BT8009 under development for the treatment of heavily pre-treated urothelial, lung and breast cancer patients. In January 2023. the company received fast track designation from the FDA for BT8009 as a monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer. As the peptide drug conjugates move along the clinical development trajectory, we expect the market to grow at a favorable CAGR during the forecast period.

Peptide Receptor Radionuclide Therapy, Generating Interest in the Pharmaceutical Industry

Peptide receptor radionuclide therapy (PRRT) candidates comprise of an antigen targeting peptide conjugated to a radioisotope / radionuclide through a linker. Novartis is currently the market leader in PRRT therapy (peptide radionuclide conjugate) market with two marketed products - Lutathera and Pluvicto. Pluvicto, received FDA and EMA approval for the treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer patients who have already been treated with other anticancer treatments in March 2022 and December 2022, respectively. Novartis recorded sales worth USD 271 million for Pluvicto in FY 2022, even though there was a supply shortage reported for the drug in the US.

With its continuous focus on research on PRRT therapy (peptide radionuclide conjugates) market, Novartis signed a collaboration agreement with Bicycle Therapeutics in March 2023 for the development of bicycle radio-conjugates, which are peptide receptor radionuclide therapy using bicyclic peptides. Later in May 2023, Bayer entered into a similar collaboration with Bicycle Therapeutics for development of peptide radioconjugates targeting cancer. There have been more such partnerships and collaborations in this emerging segment of the drug conjugates market. Looking at the successful uptake of the approved PRRT therapy candidates and the rising interest of big pharma in the PRRT therapy market, this segment will continue to witness significant market growth during the forecast period.

GalNAc Conjugates of Oligonucleotide Therapeutics Allow Targeted Delivery; Multiple Drug Conjugate Approvals are Anticipated in the Short-term

Over the past decade, oligonucleotide therapeutics have emerged as a promising therapeutic modality. Within these, the GalNAc conjugates have recently emerged as a breakthrough therapy for various rare disorders. GalNAc conjugates comprise of N-acetylgalactosamine (GalNAc) sugar molecule conjugated to an oligonucleotide. Given the affinity of GalNAc molecules to attach with the asialoglycoprotein receptor (ASGPR) of the liver cells, the GalNAc conjugated oligonucleotide therapy emerged as the dominant strategy for delivering therapeutic modality through the liver cells.

Ionis, Alnylam, Dicerna, and Suzhou Ribo Life Science are the key players involved in the development of GalNAc-conjugated oligonucleotide therapies. Amongst these players, Alnylam Pharmaceuticals has emerged as the market leader with four marketed products: Givlaari, Oxlumo, Leqvio, and Amvuttra. However, it is worth mentioning that the recent acquisition of Dicerna by Novo Nordisk in November 2021 and Ionis' collaboration with pharma giant AstraZeneca in April 2023 have increased interest among stakeholders and big pharma players in this domain. With at least 12 drug candidates from Ionis, Dicerna, and Alnylam, anticipated to receive approval in the coming years, and a robust pipeline of 21 drug candidates by Suzhou Ribo Life Sciences, it is anticipated that the segment will continue to witness significant market growth during the forecasted period.

Key Trends in the Next Generation Drug Conjugates Market

A number of stakeholders are forging alliances with other industry / non-industry players. In fact, over 75 strategic partnerships related to next generation drug conjugates, have been signed since 2018. Close to 45% of the partnerships inked in this domain are product development and commercialization agreements, indicating the efforts of stakeholders in development and commercialization of these next generation drug conjugates. It is worth highlighting that, owing to the recent increase in activity in this domain, many big pharma players have shown keen interest in entering this domain. For instance, companies such as Novartis, AstraZeneca, Janssen and others have forged strategic partnerships with these next generation drug conjugate developers, in order to gain entry into this domain.

With the ongoing research efforts for the development of next generation drug conjugates, and growing contribution of big pharma players, we believe that the next generation drug conjugates market is likely to evolve at a rapid pace, over the forecast period.

Next Generation Drug Conjugates Market Size: North America to Hold the Largest Market Share

Driven by the increasing number of R&D activities and growing demand for effective therapies for rare and oncological disorders, the next generation drug conjugates market is anticipated to witness an annualized growth rate (CAGR) of over more than 20%, during the period 2023-2035. Specifically, in terms of type of conjugates, the global market for next generation drug conjugates is anticipated to be driven by the GalNac Conjugates. Likewise, in terms of therapeutic area, the market is anticipated to be dominated by the conjugates targeting rare and oncological disorders.

In addition to it, more than 70% market share is captured by the players based in North America, of which ~60% are based in the US. This is followed by Asia-Pacific where a number of developers are engaged in the development of next generation drug conjugates. Interestingly, within Asia-Pacific, China has emerged as the leading country where majority of the next generation drug conjugate developers are based.

The recent accelerated approvals of various next generation drug conjugates, such as peptide drug conjugates, GalNac conjugates, and conjugates utilizing peptide radionuclide therapy (peptide radionuclide conjugate), along with the grant of orphan and breakthrough designations by the regulatory authorities, such as the USFDA and the EMA, has increased the overall interest and confidence of the pharmaceutical industry in these novel targeted therapies. All the above factors will contribute to a healthy market growth of the next generation drug conjugates market during the forecast period.

Leading Next Generation Drug Conjugate Developers

Examples of key players engaged in next generation drug conjugate development (which have also been captured in this report, arranged in alphabetical order) include Advanced Accelerator Applications, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Cellectar Biosciences, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, Shenzhen Ascentawits Pharmaceuticals Sirnaomics, Silence Therapeutics, and Suzhou Ribo Life Science. This market report includes an easily searchable excel database of all the next generation drug conjugate companies worldwide.

Recent Developments in Next Generation Drug Conjugates Market

Several recent developments have taken place in the field of next generation drug conjugates market, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have outlined in our analysis.

1. In April 2023, Novartis entered into a licensing agreement with 3B Pharmaceuticals. 3B Pharmaceuticals is German based company, involved in the development of peptide receptor radionuclide therapy (PRRT) candidates targeting fibroblast activation protein (FAP) receptors.

2. In March 2023, Japan based PeptiDream announced its second strategic collaboration with a US based RayzeBio for the development of peptide-radioisotope (RI) conjugate against Glypican-3 ("GPC3") expressed in liver cancers.

3. In March 2023, Ionis Pharmaceutical announced that the USFDA has accepted the New Drug Application (NDA) for its investigational antisense medicine Eplontersen for the patients suffering with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). When approved, Eplontersen will become the second drug after Alnylam's Amvuttra® (vutrisiran) for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:

An executive summary of the insights captured during our research, offering a high-level view of the current state of the next generation drug conjugates market and its likely evolution in the mid-to-long term.
A brief introduction to the next generation drug conjugates, highlighting their historical background, as well as information on their structure, advantages, and the pharmacokinetic properties of these next generation drug conjugates.
A detailed assessment of the market landscape of more than 200 next generation drug conjugates / next generation targeted therapeutics that are either approved or being evaluated in different stages of development (clinical or pre-clinical), based on several relevant parameters, such as type of conjugate (GalNac conjugate, peptide drug conjugate, peptide oligonucleotide conjugate, RNAi conjugate, peptide radionuclide conjugate, small molecule drug conjugate, and other conjugates), type of targeting ligand (amino sugar, lipid, peptide, small molecule and virus-like particles), type of payload, type of biological target, mechanism of action (sequence-specific target binding, radiation induced cytotoxicity, cancer-specific surface target mediated cytotoxicity, drug induced cytotoxicity, receptor mediated internalization and cytotoxicity and others), stage of development (preclinical, clinical and approved), phase of development (approved, phase III, phase II, phase I, preclinical and discovery), type of therapy (monotherapy and combination therapy), route of administration (intravenous, subcutaneous and others), target disease indication (muscular dystrophy, lung cancer, hepatitis, breast cancer, nonalcoholic steatohepatitis, prostate cancer, ovarian cancer, hypertension and hypertriglycedermia), therapeutic area (cardiovascular disorders, genetic disorders, hepatic disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, respiratory disorders, renal disorders, and other disorders) and target population (children, adults and older adults). In addition, the chapter features information on various next generation drug conjugate developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of drug candidates).
Elaborate profiles of leading next generation drug conjugate companies (shortlisted based on number of drug candidates in pipeline that have been approved / commercialized or being evaluated in phase III clinical trials) and their respective product portfolios. Each profile features a brief overview of the company, product portfolio, an overview of the drug candidates which are either approved or are in phase III of clinical development, along with recent developments, and an informed future outlook of the company.
An in-depth analysis of completed, ongoing, and planned clinical trials of various next generation drug conjugates, based on several relevant parameters, such as trial registration year, trial phase, trial status, enrolled patient population, type of sponsor, age group, most active industry players, leading drug candidate, primary purpose, therapeutic area and key geographical regions.
An in-depth analysis of partnerships that have been established between various stakeholders since 2018, covering acquisitions, research and development agreements, product development and commercialization agreements, platform / technology licensing agreement, service agreement, clinical trial agreement, joint venture and others.
A study of the various grants that have been awarded to research institutes engaged in conducting research related to next generation drug conjugates, since 2018, based on various important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, popular NIH departments (based on number of grants awarded), prominent program officers, leading recipient organizations and key regions.
A detailed analysis of more than 400 peer-reviewed, scientific articles focused on next generation drug conjugates that have been published since 2018, based on year of publication, type of publication, type of conjugate, target indication, copyright holders and focus area. The chapter also highlights the leading publishers and key journals (in terms of number of articles published and impact factor).
An in-depth analysis of next generation drug conjugates that failed to progress to later stages of development, based on various relevant parameters, such as trial status of discontinuation, trial phase of discontinuation, average trial year, type of therapy, target indication and reason for drug failure.
An insightful success protocol analysis of recently approved and commercialized next generation drug conjugates, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, drug designation, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.

One of the key objectives of this market report was to estimate the current market size and the future growth potential of the next generation drug conjugates over the forecast period. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the next generation drug conjugates market over the forecast period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of conjugate (peptide receptor radionuclide therapy, ligand mediated RNAi conjugates, ligand conjugates anti sense medicine and peptide drug conjugates), key target indications (gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis caused by breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, primary hyperoxaluria, heterozygous familial hypercholesterolemia, hemophilia, low-risk myelodysplastic syndrome, myelofibrosis, alpha-1 antitrypsin deficiency liver disease and familial chylomicronemia syndrome), and key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry's evolution.

All actual figures have been sourced and analyzed from publicly available information forums and secondary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary research. For all our projects, we undertake extensive secondary research in order to identify the emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary sources of information.

KEY QUESTIONS ANSWERED

Question 1: What are next generation drug conjugates?

Answer: Next generation drug conjugates are conjugates that use non-antibody-based targeting ligand for targeted therapy. These conjugates use GalNAc, small molecules, peptides, and radionuclides as their targeting ligands.

Question 2: What is GalNAc used for?

Answer: N-Acetylgalactosamine or more popularly known as the GalNac, is an amino sugar derivative of galactose. Conjugation of GalNac as a targeting ligand has emerged as dominant strategy for delivering therapeutic modalities, such as si-RNA, oligonucleotide, antisense oligonucleotide and others to the hepatocytes. Interestingly, ligand conjugated anti sense medicine and ligand mediated RNAi conjugates have emerged as the popular next generation drug conjugates in this industry.

Question 3: What are GalNAc oligonucleotide conjugates?

Answer: GalNac oligonucleotide conjugates, or more popularly known as the GalNAc conjugates, are the next generation drug conjugates, which use GalNac as their targeting ligand and oligonucleotide as their payload for targeted therapy. Owing to their clinical proficiency, structural stability, and tissue penetration, they have emerged as a popular next generation drug conjugate among the industry stakeholders.

Question 4: What are the advantages of peptide drug conjugates?

Answer: Owing to the various advantages offered by the peptides, such as limited immunogenicity within the body, better clinical profile, lesser side effects, structural stability, and ease of administration through subcutaneous administration; peptides have been successfully used to target various cell receptors for targeted therapy.

Question 5: What is peptide receptor radionuclide therapy?

Answer: Peptide receptor radionuclide therapy is a type of next generation drug conjugate, which uses peptide as the targeting ligand, and radionuclide as their cytotoxic payload, to provide targeted therapy. Lutathera® by Advanced Accelerator Applications was the first peptide receptor radionuclide therapy to be approved by the USFDA and the EMA for the treatment of neuroendocrine tumor.

Question 6: What is the likely market growth rate (CAGR) for the next generation drug conjugates market?

Answer: The market size for next generation drug conjugates market is projected to grow at an annualized rate (CAGR) of ~20%, during the forecast period 2023-2035.

Question 7: Who are the leading companies in the next generation drug conjugates market?

Answer: Some of the leading companies engaged in the next generation drug conjugates development (which have also been captured in this market report, arranged in alphabetical order) include Advanced Accelerator Applications, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Cellectar Biosciences, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, Shenzhen Ascentawits Pharmaceuticals Sirnaomics, Silence Therapeutics, and Suzhou Ribo Life Science.

CHAPTER OUTLINES

Chapter 1 is a preface providing an overview of the full report, Next Generation Drug Conjugates Market, 2023-2035.

Chapter 2 is an executive summary of the key insights captured during our research, offering a high-level view on the current state of the next generation drug conjugates market and its likely evolution in the short to mid and long term.

Chapter 3 provides a general overview of the next generation drug conjugates, highlighting their historical background, as well as information on their structure, advantages, and the pharmacokinetic properties of the various next generation drug conjugates, such as GalNac conjugates, peptide drug conjugates and others.

Chapter 4 provides information on more than 200 next generation drug conjugates / next generation targeted therapeutics that are either approved or being evaluated in different stages of development (clinical or pre-clinical), based on several relevant parameters, such as type of conjugate (GalNac conjugate, peptide drug conjugate, peptide oligonucleotide conjugate, RNAi conjugate, peptide radionuclide conjugate, small molecule drug conjugate, and other conjugates), type of targeting ligand (amino sugar, lipid, peptide, small molecule and virus-like particles), type of payload, type of biological target, mechanism of action (sequence-specific target binding, radiation induced cytotoxicity, cancer-specific surface target mediated cytotoxicity, drug induced cytotoxicity, receptor mediated internalization and cytotoxicity and others), stage of development (preclinical, clinical and approved), phase of development (approved, phase III, phase II, phase I, preclinical and discovery), type of therapy (monotherapy and combination therapy), route of administration (intravenous, subcutaneous and others), target disease indication (muscular dystrophy, lung cancer, hepatitis, breast cancer, nonalcoholic steatohepatitis, prostate cancer, ovarian cancer, hypertension and hypertriglycedermia), therapeutic area (cardiovascular disorders, genetic disorders, hepatic disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, respiratory disorders, renal disorders, and other disorders) and target population (children, adults and older adults). In addition, the chapter features information on various next generation drug conjugate developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of drug candidates).

Chapter 5 presents elaborate profiles of leading next generation drug conjugate companies (shortlisted based on number of drug candidates in pipeline that have been approved / commercialized or in Phase III of development) and their respective product portfolios. Each profile features a brief overview of the company, product portfolio, an overview of the drug candidates which are either approved or are in phase III stage of clinical development, along with recent developments, and an informed future outlook of the developer.

Chapter 6 presents an in-depth analysis of completed, ongoing, and planned clinical studies of various next generation drug conjugates, based on several relevant parameters, such as trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, age group, most active industry players, leading drug candidate, primary purpose, therapeutic area and key geographical regions.

Chapter 7 presents an in-depth analysis of partnerships that have been inked between various stakeholders since 2018, covering product development and commercialization agreement, research and development agreement, service agreement, platform / technology licensing agreement, acquisition, clinical trial agreement, product licensing agreement, joint ventures and others.

Chapter 8 provides information on study of the various grants that have been awarded to research institutes engaged in conducting research related to next generation drug conjugates, since 2018, based on various important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, popular NIH departments (based on number of grants awarded), prominent program officers, leading recipient organizations and key regions.

Chapter 9 features an in-depth analysis of more than 400 peer-reviewed, scientific articles focused on next generation drug conjugates that have been published since 2018, based on year of publication, type of publication, number of publications, type of conjugate, target indication and copyright holders. The chapter also highlights the leading publishers and key journals (in terms of number of articles published and impact factor).

Chapter 10 presents a comprehensive analysis of the next generation drug conjugates that failed to progress to later stages of clinical development, based on various relevant parameters, such as trial status of discontinuation, trial phase of discontinuation, average trial year, type of therapy, target indication and reason for drug failure.

Chapter 11 features insightful success protocol analysis of recently approved and commercialized next generation drug conjugates, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, drug designation, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.

Chapter 12 features an elaborate market forecast analysis, highlighting the likely growth of the next generation drug conjugates market, till the year 2035. In order to provide details on future opportunity, our projections have been segmented on the basis of type of conjugate (peptide receptor radionuclide therapy, ligand mediated RNAi conjugates, ligand conjugates anti sense medicine and peptide drug conjugates), key target indications (gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis caused by breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, primary hyperoxaluria, heterozygous familial hypercholesterolemia, hemophilia, low-risk myelodysplastic syndrome, myelofibrosis, alpha-1 antitrypsin deficiency liver disease and familial chylomicronemia syndrome), and key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry's evolution.

Chapter 13 is an appendix, which contains tabulated data and numbers for all the figures included in this report.

Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.

1. PREFACE

1.1. Next Generation Drug Conjugates Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Overview of Next Generation Drug Conjugates
3.2. Key Historical Events
3.3. Structure of Next Generation Drug Conjugates
3.4. Biochemical Interaction and Mechanism of Action
3.5. Key Target Indications
3.6. Advantages of Next Generation Drug Conjugates
3.7 Challenges associated with Next Generation Drug Conjugates
3.8. Future Perspectives

4. MARKET LANDSCAPE

4.1. Methodology
4.2. Next Generation Drug Conjugates: List of Therapies
- 4.2.1. Analysis by Type of Conjugate
- 4.2.2. Analysis by Type of Targeting Ligand
- 4.2.3. Analysis by Type of Payload
- 4.2.4. Analysis by Biological Target
- 4.2.5. Analysis by Mechanism of Action
- 4.2.6. Analysis by Stage of Development
- 4.2.7. Analysis by Phase of Development
- 4.2.8. Analysis by Type of Therapy
- 4.2.9. Analysis by Route of Administration
- 4.2.10. Analysis by Target Disease Indication
- 4.2.11. Analysis by Therapeutic Area
- 4.2.12. Analysis by Target Population
- 4.2.13. Analysis by Type of Conjugate and Stage of Development
- 4.2.14. Analysis by Type of Conjugate and Target Population
4.3 Next Generation Drug Conjugates: Developer Landscape
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters (Region-wise)
- 4.3.4. Analysis by Location of Headquarters (Country-wise)
- 4.3.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
- 4.3.6. Most Active Players: Analysis by Number of Drug Candidates

5. COMPANY AND DRUG PROFILES

5.1. Advanced Accelerator Applications
- 5.1.1. Company Overview
- 5.1.2. Management Team
- 5.1.3. Product Portfolio
  - 5.1.3.1. Lutathera®
    - 5.1.3.1.1 Drug Overview
    - 5.1.3.1.2. Clinical Trial Information
    - 5.1.3.1.3. Clinical Trial Results
    - 5.1.3.1.4. Dosing Regimen
    - 5.1.3.1.5. Estimated Sales
  - 5.1.3.2. Pluvicto®
    - 5.1.3.2.1 Drug Overview
    - 5.1.3.2.2. Clinical Trial Information
    - 5.1.3.2.3. Clinical Trial Results
    - 5.1.3.2.4. Dosing Regimen
    - 5.1.3.2.5. Estimated Sales
- 5.1.4. Recent Developments and Future Outlook
5.2. Alnylam Pharmaceuticals
- 5.2.1. Company Overview
- 5.2.2. Management Team
- 5.2.3. Product Portfolio
  - 5.2.3.1. Givlaari®
    - 5.2.3.1.1. Drug Overview
    - 5.2.3.1.2. Clinical Trial Information
    - 5.2.3.1.3. Clinical Trial Results
    - 5.2.4.1.4. Dosing Regimen
  - 5.2.3.2. Oxlumo®
    - 5.2.3.2.1. Drug Overview
    - 5.2.3.2.2. Clinical Trial Information
    - 5.2.3.2.3. Clinical Trial Results
    - 5.2.3.2.4. Dosing Regimen
  - 5.2.3.3. Leqvio®
    - 5.2.3.3.1. Drug Overview
    - 5.2.3.3.2. Clinical Trial Information
    - 5.2.3.3.3. Clinical Trial Results
    - 5.2.3.3.4. Dosing Regimen
  - 5.2.3.4. Amvuttra®
    - 5.2.3.4.1. Drug Overview
    - 5.2.3.4.2. Clinical Trial Information
    - 5.2.3.4.3. Clinical Trial Results
    - 5.2.3.4.4. Dosing Regimen
- 5.2.4. Recent Developments and Future Outlook
5.3. Arrowhead Pharmaceuticals
- 5.3.1. Company Overview
- 5.3.2. Management Team
- 5.3.3. Product Portfolio
  - 5.3.3.1. Olpasiran
    - 5.3.3.1.1. Drug Overview
    - 5.3.3.1.2. Clinical Trial Information
    - 5.3.3.1.3. Clinical Trial Results
    - 5.3.3.1.4. Dosing Regimen
  - 5.3.3.2. ARO-AAT
    - 5.3.3.2.1. Drug Overview
    - 5.3.3.2.2. Clinical Trial Information
    - 5.3.3.2.3. Clinical Trial Results
    - 5.3.3.2.4. Dosing Regimen
  - 5.3.3.3. ARO-APOC3
    - 5.3.3.3.1. Drug Overview
    - 5.3.3.3.2. Clinical Trial Information
    - 5.3.3.3.3. Clinical Trial Results
    - 5.3.3.3.4. Dosing Regimen
- 5.3.4. Recent Developments and Future Outlook
5.4. Dicerna Pharmaceuticals
- 5.4.1. Company Overview
- 5.4.2. Management Team
- 5.4.3. Product Portfolio
  - 5.4.3.1. Nedosiran
    - 5.4.3.1.1 Drug Overview
    - 5.4.3.1.2. Clinical Trial Information
    - 5.4.3.1.3. Clinical Trial Results
    - 5.4.3.1.4. Dosing Regimen
- 5.4.4. Recent Developments and Future Outlook
5.5. Geron
- 5.5.1. Company Overview
- 5.5.2. Management Team
- 5.5.3. Product Portfolio
  - 5.5.3.1. Imtelstat
    - 5.5.3.1.1. Drug Overview
    - 5.5.3.1.2. Clinical Trial Information
    - 5.5.3.1.3. Clinical Trial Results
    - 5.5.3.1.4. Dosing Regimen
- 5.5.4. Recent Developments and Future Outlook
5.6. Ionis Pharmaceuticals
- 5.6.1. Company Overview
- 5.6.2. Management Team
- 5.6.3. Product Portfolio
  - 5.6.3.1. Eplontersen
    - 5.6.3.1.1 Drug Overview
    - 5.6.3.1.2. Clinical Trial Information
    - 5.6.3.1.3. Clinical Trial Results
    - 5.6.3.1.4. Dosing Regimen
  - 5.6.3.2. Olezarsen
    - 5.6.3.2.1. Drug Overview
    - 5.6.3.2.2. Clinical Trial Information
    - 5.6.3.2.3. Clinical Trial Results
    - 5.6.3.2.4. Dosing Regimen
  - 5.6.3.3. Pelacarsen
    - 5.6.3.3.1. Drug Overview
    - 5.6.3.3.2. Clinical Trial Information
    - 5.6.3.3.3. Clinical Trial Results
    - 5.6.3.3.4. Dosing Regimen
    - 5.6.3.3.5. Estimated Sales
  - 5.6.3.4. Donidalorsen
    - 5.6.3.4.1 Drug Overview
    - 5.6.3.4.2. Clinical Trial Information
    - 5.6.3.4.3. Clinical Trial Results
    - 5.6.3.4.4. Dosing Regimen
- 5.6.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

6.1. Analysis Methodology and Key Parameters
6.2. Next Generation Drug Conjugates: Clinical Trial Analysis
- 6.2.1. Analysis by Trial Registration Year
- 6.2.2. Analysis by Trial Phase
- 6.2.3. Analysis by Trial Status
- 6.2.4. Analysis by Therapeutic Area
- 6.2.5. Analysis by Primary Purpose
- 6.2.6. Analysis by Age Group
- 6.2.7. Analysis by Type of Sponsor
- 6.2.8. Most Active Industry Players: Analysis by Number of Trials
- 6.2.9. Leading Drug Candidates: Analysis by Number of Trials
- 6.2.10. Analysis by Trial Registration Year and Trial Location
- 6.2.11. Analysis by Trial Registration Year and Enrolled Patient Population
- 6.2.12. Analysis by Trial Phase and Enrolled Patient Population
- 6.2.13. Analysis by Trial Status and Enrolled Patient Population
- 6.2.14. Analysis by Trial Location and Enrolled Patient Population
- 6.2.15. Analysis by Trial Status and Trial Location

7. PARTNERSHIPS AND COLLABORATIONS

7.1. Partnership Models
7.2. Next Generation Drug Conjugates: Partnerships and Collaborations
- 7.3.1. Analysis by Year of Partnership
- 7.3.2. Analysis by Type of Partnership
- 7.3.3. Analysis by Year and Type of Partnership
- 7.3.4. Analysis by Type of Partner
- 7.3.5. Analysis by Year of Partnership and Type of Partner
- 7.3.6. Analysis by Type of Partnership and Type of Partner
- 7.3.7. Analysis by Type of Partner and Parent Company Size
- 7.3.8. Analysis by Therapeutic Area
- 7.3.9. Most Active Players: Analysis by Number of Partnerships
- 7.3.10. Analysis by Geography
  - 7.3.10.1. Analysis by Type of Geography (Region-wise)
  - 7.3.10.2. Analysis by Type of Geography (Country-wise)
  - 7.3.10.3. Intercontinental and Intracontinental Agreements

8. ACADEMIC GRANTS ANALYSIS

8.1. Methodology and Key Parameters
8.2. Next Generation Drug Conjugates: Academic Grants Analysis
- 8.2.1. Analysis by Year of Grant Award
- 8.2.2. Analysis by Amount Awarded
- 8.2.3. Analysis by Funding Institute Center
- 8.2.4. Analysis by Support Period
- 8.2.5. Analysis by Funding Institute Center and Support Period
- 8.2.6. Analysis by Type of Grant Application
- 8.2.7. Analysis by Purpose of Grant
- 8.2.8. Analysis by Activity Code
- 8.2.9. Analysis by Study Section
- 8.2.10. Popular NIH Departments: Analysis by Number of Grants
- 8.2.11. Analysis by Type of Recipient Organization
  - 8.2.11.1. Popular Recipient Organizations: Analysis by Number of Grants
  - 8.2.11.2. Popular Recipient Organizations: Analysis by Amount Awarded
- 8.2.12. Prominent Program Officers: Analysis by Number of Grants
- 8.2.13 Analysis by Location of Recipient Organizations

9. PUBLICATION ANALYSIS

9.1. Analysis Methodology and Key Parameters
9.2. Next Generation Drug Conjugates: Publication Analysis
- 9.2.1. Analysis by Year of Publication
- 9.2.2. Analysis by Type of Publication
- 9.2.3. Analysis by Type of Conjugate
- 9.2.4. Analysis by Target Indication
- 9.2.5. Analysis by Copyright Holder
- 9.2.6. Word Cloud: Emerging Focus Area
- 9.2.7. Most Active Publishers: Analysis by Number of Publications
- 9.2.8. Key Journals: Analysis by Number of Publications
- 9.2.9. Key Journals: Analysis by Impact Factor

10. DRUG FAILURE ANALYSIS

10.1. Analysis Methodology and Key Parameters
10.2. Next Generation Drug Conjugates: Drug Failure Analysis
- 10.2.1. Analysis by Status of Discontinuation
- 10.2.2. Analysis by Phase of Discontinuation
- 10.2.3. Analysis by Average Trial Year
- 10.2.4. Analysis by Type of Therapy
- 10.2.5. Analysis by Target Indication
- 10.2.6. Analysis by Reason for Drug Failure

11. SUCCESS PROTOCOL ANALYSIS

11.1. Methodology and Key Parameters
11.2. Key Assumptions and Scoring Criteria
11.3. Success Protocol Analysis
11.4. Assessment of Approved Next Generation Drug Conjugates: Harvey Ball Analysis

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12.1. Key Assumptions and Forecast Methodology
12.2. Next Generation Drug Conjugates Market, 2023-2035
- 12.2.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035
  - 12.2.1.1. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, 2023-2035
  - 12.2.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, 2023-2035
  - 12.2.1.3. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, 2023-2035
  - 12.2.1.4. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, 2023-2035
- 12.2.2. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand
  - 12.2.2.1 Next Generation Drug Conjugates Market for Amino Sugars, 2023-2035
  - 12.2.2.2 Next Generation Drug Conjugates Market for Peptides, 2023-2035
  - 12.2.2.3 Next Generation Drug Conjugates Market for Lipids, 2023-2035
- 12.2.3. Next Generation Drug Conjugates Market: Distribution by Payload
  - 12.2.3.1. Next Generation Drug Conjugates Market for Radionuclides, 2023-2035
  - 12.2.3.2. Next Generation Drug Conjugates Market for Drugs, 2023-2035
  - 12.2.3.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, 2023-2035
  - 12.2.3.4 Next Generation Drug Conjugates Market for si-RNAs, 2023-2035
- 12.2.4. Next Generation Drug Conjugates Market: Distribution by Therapy
  - 12.2.4.1. Next Generation Drug Conjugates Market for Monotherapy, 2023-2035
  - 12.2.4.2. Next Generation Drug Conjugates Market for Combination Therapy, 2023-2035
- 12.2.5. Next Generation Drug Conjugates Market: Distribution by Route of Administration
  - 12.2.5.1. Next Generation Intravenous Drug Conjugates Market, 2023-2035
  - 12.2.5.2. Next Generation Subcutaneous Drug Conjugates Market, 2023-2035
- 12.2.6. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
  - 12.2.6.1. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, 2023-2035
  - 12.2.6.2. Next Generation Drug Conjugates Market for Prostate Cancer, 2023-2035
  - 12.2.6.3. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, 2023-2035
  - 12.2.6.4. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, 2023-2035
  - 12.2.6.5. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, 2023-2035
  - 12.2.6.6. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, 2023-2035
  - 12.2.6.7. Next Generation Drug Conjugates Market for Hereditary Angioedema, 2023-2035
  - 12.2.6.8. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, 2023-2035
  - 12.2.5.9. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, 2023-2035
  - 12.2.5.10. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, 2023-2035
  - 12.2.5.11. Next Generation Drug Conjugates Market for Hemophilia, 2023-2035
  - 12.2.5.12. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, 2023-2035
  - 12.2.5.13. Next Generation Drug Conjugates Market for Myelofibrosis, 2023-2035
  - 12.2.5.14. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, 2023-2035
  - 12.2.5.15. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, 2023-2035
- 12.2.6. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035
  - 12.2.6.1. Next Generation Drug Conjugates Market in North America, 2023-2035
    - 12.2.6.1.1. Next Generation Drug Conjugates Market in the US, 2022-2035
    - 12.2.6.1.2. Next Generation Drug Conjugates Market in Canada, 2022-2035
  - 12.2.6.2. Next Generation Drug Conjugates Market in Europe, 2023-2035
    - 12.2.6.2.1. Next Generation Drug Conjugates Market in the UK, 2022-2035
    - 12.2.6.2.2. Next Generation Drug Conjugates Market in France, 2022-2035
    - 12.2.6.2.3. Next Generation Drug Conjugates Market in Germany, 2022-2035
    - 12.2.6.2.4. Next Generation Drug Conjugates Market in Spain, 2022-2035
    - 12.2.6.2.5. Next Generation Drug Conjugates Market in Italy, 2022-2035
    - 12.2.6.2.6. Next Generation Drug Conjugates Market in Rest of the Europe, 2022-2035
  - 12.2.6.3. Next Generation Drug Conjugates Market in Asia-Pacific and Rest of the World, 2023-2035
    - 12.2.6.3.1. Next Generation Drug Conjugates Market in Japan, 2023-2035
    - 12.2.6.3.2. Next Generation Drug Conjugates Market in Australia, 2023-2035
    - 12.2.6.3.3. Next Generation Drug Conjugates Market in Brazil, 2023-2035
12.3. Next Generation Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
- 12.3.1. Lutathera®
  - 12.3.1.1. Sales Forecast (USD Million)
  - 12.3.1.2. Net Present Value (USD Million)
  - 12.3.1.3. Value Creation Analysis
- 12.3.2. Pluvicto®
  - 12.3.2.1. Sales Forecast (USD Million)
  - 12.3.2.2. Net Present Value (USD Million)
  - 12.3.2.3. Value Creation Analysis
- 12.3.3. Givlaari®
  - 12.3.3.1. Sales Forecast (USD Million)
  - 12.3.3.2. Net Present Value (USD Million)
  - 12.3.3.3. Value Creation Analysis
- 12.3.4. Oxlumo®
  - 12.3.4.1. Sales Forecast (USD Million)
  - 12.3.4.2. Net Present Value (USD Million)
  - 12.3.4.3. Value Creation Analysis
- 12.3.5. Leqvio®
  - 12.3.5.1. Sales Forecast (USD Million)
  - 12.3.5.2. Net Present Value (USD Million)
  - 12.3.5.3. Value Creation Analysis
- 12.3.6. Amvuttra®
  - 12.3.6.1. Sales Forecast (USD Million)
  - 12.3.6.2. Net Present Value (USD Million)
  - 12.3.6.3. Value Creation Analysis
- 12.3.7. Eplontersen
  - 12.3.7.1. Sales Forecast (USD Million)
  - 12.3.7.2. Net Present Value (USD Million)
  - 12.3.7.3. Value Creation Analysis
- 12.3.8. Olezarsen
  - 12.3.8.1. Sales Forecast (USD Million)
  - 12.3.8.2. Net Present Value (USD Million)
  - 12.3.8.3. Value Creation Analysis
- 12.3.9. Pelacarsen
  - 12.3.9.1. Sales Forecast (USD Million)
  - 12.3.9.2. Net Present Value (USD Million)
  - 12.3.9.3. Value Creation Analysis
- 12.3.10. Donidalorsen
  - 12.3.10.1. Sales Forecast (USD Million)
  - 12.3.10.2. Net Present Value (USD Million)
  - 12.3.10.3. Value Creation Analysis
- 12.3.11. Fitusiran
  - 12.3.11.1. Sales Forecast (USD Million)
  - 12.3.11.2. Net Present Value (USD Million)
  - 12.3.11.3. Value Creation Analysis
- 12.3.12. Nedosiran
  - 12.3.12.1. Sales Forecast (USD Million)
  - 12.3.12.2. Net Present Value (USD Million)
  - 12.3.12.3. Value Creation Analysis
- 12.3.13. Imetlestat
  - 12.3.13.1. Sales Forecast (USD Million)
  - 12.3.13.2. Net Present Value (USD Million)
  - 12.3.13.3. Value Creation Analysis
- 12.3.14. Olpasiran
  - 12.3.14.1. Sales Forecast (USD Million)
  - 12.3.14.2. Net Present Value (USD Million)
  - 12.3.14.3. Value Creation Analysis
- 12.3.15. ARO-AAT
  - 12.3.15.1. Sales Forecast (USD Million)
  - 12.3.15.2. Net Present Value (USD Million)
  - 12.3.15.3. Value Creation Analysis
- 12.3.16. ARO-APOC3
  - 12.3.16.1. Sales Forecast (USD Million)
  - 12.3.16.2. Net Present Value (USD Million)
  - 12.3.16.3. Value Creation Analysis
- 12.3.17. ANG-1005
  - 12.3.17.1. Sales Forecast (USD Million)
  - 12.3.17.2. Net Present Value (USD Million)
  - 12.3.17.3. Value Creation Analysis

次世代薬物複合体市場-GalNac/ペプチド薬物/ペプチドオリゴヌクレオチド＆RNAi複合体、ペプチド受容体放射性核種療法、その他の複合体-主要地域：業界動向と世界の予測、2023年～2035年

Next Generation Drug Conjugates Market-Focus on GalNac/Peptide Drug/Peptide Oligonucleotide & RNAi Conjugate, Peptide Receptor Radionuclide Therapy, & Other Conjugates-Key Geographical Regions: Industry Trends & Global Forecasts, 2023-2035

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 市場情勢

第5章 企業および薬剤プロファイル

第6章 臨床試験の分析

第7章 パートナーシップとコラボレーション

第8章 学術助成金の分析

第9章 出版物の分析

第10章 薬剤失敗の分析

第11章 成功プロトコルの分析

第12章 市場予測と機会分析

第13章 付録1：表形式のデータ

第14章 付録2：企業および組織のリスト

List of Tables

List of Figures

INTRODUCTION

SCOPE OF THE REPORT

Current Market Landscape: Next Generation Drug Conjugates Revolutionizing the Treatment for Cancer and Rare Diseases

Peptide Drug Conjugate, Next Generation of Targeted Therapeutics in Clinical Trial as Anticancer Agents

Peptide Receptor Radionuclide Therapy, Generating Interest in the Pharmaceutical Industry

GalNAc Conjugates of Oligonucleotide Therapeutics Allow Targeted Delivery; Multiple Drug Conjugate Approvals are Anticipated in the Short-term

Key Trends in the Next Generation Drug Conjugates Market

Next Generation Drug Conjugates Market Size: North America to Hold the Largest Market Share

Leading Next Generation Drug Conjugate Developers

Recent Developments in Next Generation Drug Conjugates Market

RESEARCH METHODOLOGY

The secondary sources of information include:

KEY QUESTIONS ANSWERED

Question 1: What are next generation drug conjugates?

Question 2: What is GalNAc used for?

Question 3: What are GalNAc oligonucleotide conjugates?

Question 4: What are the advantages of peptide drug conjugates?

Question 5: What is peptide receptor radionuclide therapy?

Question 6: What is the likely market growth rate (CAGR) for the next generation drug conjugates market?

Question 7: Who are the leading companies in the next generation drug conjugates market?

CHAPTER OUTLINES

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. COMPANY AND DRUG PROFILES

6. CLINICAL TRIAL ANALYSIS

7. PARTNERSHIPS AND COLLABORATIONS

8. ACADEMIC GRANTS ANALYSIS

9. PUBLICATION ANALYSIS

10. DRUG FAILURE ANALYSIS

11. SUCCESS PROTOCOL ANALYSIS

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

第1章序文

第2章エグゼクティブサマリー

第3章イントロダクション

第4章市場情勢

第5章企業および薬剤プロファイル

第6章臨床試験の分析

第7章パートナーシップとコラボレーション

第8章学術助成金の分析

第9章出版物の分析

第10章薬剤失敗の分析

第11章成功プロトコルの分析

第12章市場予測と機会分析

第13章付録1：表形式のデータ

第14章付録2：企業および組織のリスト